- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Monitor endometrioma size of participants: CDSCO panel tells Abbott India on Dydrogesterone
Overview
Suggesting monitoring the size of the endometrioma of participating subjects during the clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Abbott India to conduct the Phase III clinical trial and bioequivalence (BE) study of Dydrogesterone Sustained Release Suggesting monitoring the size of the endometrioma of participating subjects during the clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Abbott India to conduct the Phase III clinical trial and bioequivalence (BE) study of Dydrogesterone Sustained Release Tablets 20mg, an orally active progestogen that acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.
For more details, check out the full story on the link below:
Monitor endometrioma size of participants: CDSCO panel tells Abbott India on Dydrogesterone
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed